Results 41 to 50 of about 5,090 (179)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

OncoImmunology, 2019
In a recent edition of Science Translational Medicine, we identified an enhanced therapeutic activity when talimogene laherparepvec (T-VEC) was combined with MEK inhibition in murine melanoma tumor models.
Praveen K. Bommareddy, Samuel D. Rabkin, Howard L. Kaufman   +2 more
doaj   +1 more source

Advances in immunotherapy for melanoma [PDF]

, 2016
In recent years, the introduction and Federal Drug Administration approval of immune checkpoint inhibitor antibodies has dramatically improved the clinical outcomes for patients with advanced melanoma.
Geoffrey T. Gibney, Jason M. Redman, Michael B. Atkins   +2 more
core   +1 more source

Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs [PDF]

, 2013
Oncolytic viruses are emerging as a potential new way of treating cancers. They are selectively replication-competent viruses that propagate only in actively dividing tumor cells but not in normal cells and, as a result, destroy the tumor cells by ...
Braidwood, L., Conner, J., Graham, A., Graham, S.V.   +3 more
core   +1 more source

Strategies for Advanced Oncolytic Virotherapy: Current Technology Innovations and Clinical Approaches

Pharmaceutics, 2022
Oncolytic virotherapy is a type of nanomedicine with a dual antitumor mechanism. Viruses are engineered to selectively infect and lyse cancer cells directly, leading to the release of soluble antigens which induce systemic antitumor immunity ...
Qing Ji, Yuchen Wu, Andreas Albers, Meiyu Fang, Xu Qian   +4 more
doaj   +1 more source

An update on GM-CSF and its potential role in melanoma management

Melanoma Management, 2020
GM-CSF drives the differentiation of granulocytes and monocyte/macrophages from hematopoietic stem cell progenitors. It is required for differentiating monocytes into dendritic cells (DC).
Robert O Dillman
doaj   +1 more source

Oncolytic viruses in melanoma

Frontiers in Bioscience-Landmark, 2022
Malignant melanoma recurrence remains heterogeneous in presentation, ranging from locoregional disease (i.e., local recurrence, satellites, in transit disease) to distant dermal and visceral metastases.
Camille Robinson, Maria M Xu, Smita K Nair, Georgia M Beasley, Kristen E Rhodin   +4 more
doaj   +1 more source

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies

Biomedicines, 2017
Oncolytic virotherapy represents a novel therapeutic strategy in the treatment of gastrointestinal malignancies. Oncolytic viruses, including genetically engineered and naturally occurring viruses, can selectively replicate in and induce tumor cell ...
Daniel H. Ahn, Tanios Bekaii-Saab
doaj   +1 more source

Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages

Cancer Cell International, 2023
Squamous cell carcinomas are the most common head and neck malignancies. Significant progress has been made in standard therapeutic methods combining surgery, radiation, and chemotherapy. Nevertheless, the 5-year survival rate remains at 40–50%.
Hui Dong, Mengli Li, Chen Yang, Wei Wei, Xianglei He, Gang Cheng, Shibing Wang   +6 more
doaj   +1 more source

Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

Molecular Therapy: Oncolytics, 2019
Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly.
Meijun Zheng, Jianhan Huang, Aiping Tong, Hui Yang   +3 more
doaj   +1 more source

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma

Case Reports in Oncological Medicine, 2019
Talimogene laherparepvec is a novel, genetically engineered, oncolytic herpes virus approved for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
Umang Swami, Brian Swick, Yousef Zakharia, Mohammed Milhem   +3 more
doaj   +1 more source